Alpine Immune Sciences/ALPN

$64.37

-0.15%
-
1D1W1MYTD1YMAX

About Alpine Immune Sciences

Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company, which is engaged in discovering and developing protein-based immunotherapies to treat autoimmune and inflammatory diseases. The Company’s approach includes a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Its ALPN-303 (povetacicept) is a dual antagonist of the B cell activating factor (BAFF) and a proliferation, inducing ligand (APRIL), cytokines, which play key roles in the pathogenesis of multiple autoimmune diseases via their contribution to the activation, differentiation and/or survival of B cells, particularly antibody-secreting cells, as well as T cells and innate immune cells. Its ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator (ICOS), and CD28 antagonist intended for the treatment of autoimmune and inflammatory diseases.

Ticker

ALPN

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mitchell Gold

Employees

142

Headquarters

Seattle, United States

ALPN Metrics

BasicAdvanced
$3.08B
Market cap
-
P/E ratio
-$0.68
EPS
1.14
Beta
-
Dividend rate
$3.08B
1.13728
$47.84
$6.71
1.4M
7.862
-9.66%
-12.69%
-11.36%
52.369
8.656
9.402
95.84%
60.96%
84.76%

What the Analysts think about ALPN

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 8 analysts.
3.09% downside
High $65.00
Low $44.00
$64.37
Current price
$62.38
Average price target

ALPN Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
19.15% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$30.8M
208%
Net income
$5.9M
-150.43%
Profit margin
19.15%
-116.37%

ALPN Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 135.74%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.28
-$0.27
-$0.24
$0.12
-
Expected
-$0.37
-$0.37
-$0.33
-$0.34
-$0.42
Surprise
-24.45%
-27.87%
-28.24%
-135.74%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Alpine Immune Sciences stock?

Alpine Immune Sciences (ALPN) has a market cap of $3.08B as of April 13, 2024.

What is the P/E ratio for Alpine Immune Sciences stock?

The price to earnings (P/E) ratio for Alpine Immune Sciences (ALPN) stock is 0 as of April 13, 2024.

Does Alpine Immune Sciences stock pay dividends?

No, Alpine Immune Sciences (ALPN) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Alpine Immune Sciences dividend payment date?

Alpine Immune Sciences (ALPN) stock does not pay dividends to its shareholders.

What is the beta indicator for Alpine Immune Sciences?

Alpine Immune Sciences (ALPN) has a beta rating of 1.14. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Alpine Immune Sciences stock price target?

The target price for Alpine Immune Sciences (ALPN) stock is $62.38, which is 3.09% below the current price of $64.37. This is an average based on projections from 8 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Alpine Immune Sciences stock

Buy or sell Alpine Immune Sciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing